Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Core Points - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [1][6] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for treating adult patients with MASH [6] Financial Summary - As of June 30, 2025, the liquidity account had cash resources of €428,212.57, with a total of 84,532 shares available [3] - The number of executions on the buy side for the semester was 1,642, with a traded volume of 267,584 shares for €744,692.94, while the sell side had 1,878 executions and a traded volume of 296,504 shares for €819,771.51 [3] - The previous half-year report as of December 31, 2024, indicated cash resources of €349,630.55 and 113,452 shares available [3] Trading Activity - The trading activity for the buy side included various dates with notable volumes, such as 2,741 shares traded for €5,865.74 on February 1, 2025, and 2,000 shares for €4,580.00 on February 10, 2025 [2][4] - The sell side also showed significant activity, with 14,338 shares traded for €34,267.82 on January 23, 2025, and 9,521 shares for €26,373.17 on February 24, 2025 [2][4] Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq Global Market, indicating its presence in both European and American markets [7] - The company aims to address significant unmet medical needs through its innovative therapies, particularly focusing on chronic liver diseases [6]